International Clinical Trial: Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07215078) titled 'Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants' on Oct. 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Pfizer

Condition: Healthy Volunteer

Intervention: Drug: atirmociclib (PF-07220060)

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: October 8, 2025

Target Sample Size: 72

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT0...